Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Human Interleukin-2 Receptor

The Human Interleukin-2 Receptor Warner C. Greene Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 Warren J. Leonard Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205 OVERVIEW OF INTERLEUKIN-2 (IL-2) AND IL-2 RECEPTORS In 1 976, Morgan et al first reported the presence of a T-cell growth­ promoting activity in the supernatants of activated T-cell cultures; they denoted this T-cell growth factor (TCGF) (1). In subsequent years, TCGF was characterized as a distinct biochemical entity and found to be a 15,500dalton glycoprotein (2). TCGF was purified to homogeneity (3), molecu­ larly cloned (4), and cDNAs expressed in eukaryotic cells. The entire gene has now been sequenced (5, 6) and localized to human chromosome 4 (7). TCGF, or interleukin-2 (IL-2) as it is now denoted, has played a key role in the study ofT-cell biology. This lymphokine has permitted both the long­ term growth and the cloning of hurnan and murine T-cell lines displaying helper and cytotoxic T-cell function (8). Furthermore, possible therapeutic effects of IL-2 in various malignancies and immunodeficiency states are now under study. IL-2 is not produced by resting T cells; however, following activation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Immunology Annual Reviews

The Human Interleukin-2 Receptor

Annual Review of Immunology , Volume 4 (1) – Apr 1, 1986

Loading next page...
 
/lp/annual-reviews/the-human-interleukin-2-receptor-VhUNTrkv7w

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Annual Reviews
Copyright
Copyright 1986 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0732-0582
eISSN
1545-3278
DOI
10.1146/annurev.iy.04.040186.000441
pmid
3011033
Publisher site
See Article on Publisher Site

Abstract

Warner C. Greene Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 Warren J. Leonard Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205 OVERVIEW OF INTERLEUKIN-2 (IL-2) AND IL-2 RECEPTORS In 1 976, Morgan et al first reported the presence of a T-cell growth­ promoting activity in the supernatants of activated T-cell cultures; they denoted this T-cell growth factor (TCGF) (1). In subsequent years, TCGF was characterized as a distinct biochemical entity and found to be a 15,500dalton glycoprotein (2). TCGF was purified to homogeneity (3), molecu­ larly cloned (4), and cDNAs expressed in eukaryotic cells. The entire gene has now been sequenced (5, 6) and localized to human chromosome 4 (7). TCGF, or interleukin-2 (IL-2) as it is now denoted, has played a key role in the study ofT-cell biology. This lymphokine has permitted both the long­ term growth and the cloning of hurnan and murine T-cell lines displaying helper and cytotoxic T-cell function (8). Furthermore, possible therapeutic effects of IL-2 in various malignancies and immunodeficiency states are now under study. IL-2 is not produced by resting T cells; however, following activation

Journal

Annual Review of ImmunologyAnnual Reviews

Published: Apr 1, 1986

There are no references for this article.